Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor
Authors:
- Bertrand AllardBABertrand Allard
- Anne WijkhuisenAWAnne Wijkhuisen
- Aurélie BorrullABAurélie Borrull
- Frederique DeshayesFDFrederique Deshayes
- Fabienne PriamFPFabienne Priam
- Patricia LamourettePLPatricia Lamourette
- Frédéric DucancelFDFrédéric Ducancel
- Didier BoquetDBDidier Boquet
- Jean-Yves CouraudJCJean-Yves Couraud
Open Access
- 1 January 2013
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 5 (1) , 56-69
Abstract
Endothelin B receptor (ETBR) is a G protein-coupled receptor able to bind equally to the three identified human endothelin peptides. It is expressed primarily on vascular endothelial cells and involved in various physiological processes including vascular tone homeostasis, enteric nervous system development, melanogenesis and angiogenesis. Furthermore, overactivation or overexpression of ETBR have been associated with the development of various diseases such as cardiovascular disorders and cancers. Therefore, ETBR appears to be relevant target for the therapy or diagnosis of highly prevalent human diseases. In this study, we report the in vitro characterization of rendomab-B1, a monoclonal antibody (mAb) obtained by genetic immunization, which selectively recognizes the native form of human ETBR (hETBR). Rendomab-B1 is the first-reported mAb that behaves as a potent antagonist of hETBR. It recognizes an original extracellular conformational epitope on the receptor, distinct from the endothelin-1 (ET-1) binding site. Rendomab-B1 not only blocks ET-1-induced calcium signaling pathway and triggers rapid receptor internalization on recombinant hETBR-expressing cells, but also exerts pharmacological activities on human vascular endothelial cells, reducing both cell viability and ET-1-induced hETBR synthesis. In addition, binding experiments using rendomab-B1 on different melanoma cell lines reveal the structural and functional heterogeneity of hETBR expressed at the surface of these cancer cells, strongly suggesting the existence of tumor-specific receptors. Collectively, our results underscore the value of rendomab-B1 for research, therapeutic and diagnostic applications dealing with hETBR.Keywords
This publication has 57 references indexed in Scilit:
- Electroporation-Aided DNA Immunization Generates Polyclonal Antibodies Against the Native Conformation of Human Endothelin B ReceptorDNA and Cell Biology, 2011
- Tumor immune surveillance and ovarian cancerCancer and Metastasis Reviews, 2011
- Therapeutic antibodies directed at G protein-coupled receptorsmAbs, 2010
- Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacityMedical Microbiology and Immunology, 2010
- Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cellsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.Canadian Journal of Physiology and Pharmacology, 2010
- Stromal endothelin B receptor–deficiency inhibits breast cancer growth and metastasisMolecular Cancer Therapeutics, 2009
- Endothelin Receptor Dimers Evaluated by FRET, Ligand Binding, and Calcium MobilizationBiophysical Journal, 2008
- Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerBritish Journal of Cancer, 2007
- Seven-transmembrane receptorsNature Reviews Molecular Cell Biology, 2002
- Isolation of anti-endothelin receptor monoclonal antibodies for use in receptor characterizationBiochemical and Biophysical Research Communications, 1990